tbuckley/cabot-search huggingface dataset:
1083P KEYMAKER 02B: A randomized trial of pembrolizumab (pembro) alone or with investigational agents as first-line treatment for advanced melanoma
Authors: R. Dummer, R. Shapira, J. Pigozzo, P.A. Ascierto, C. Gaudy Marqueste, D. Portnoy, M. Del Vecchio, G. Bar-Sela, J.E. Cohen, A.M. Di Giacomo, A. Ribas, C. Dutriaux, C. Belli, G. Cohen, R. Dokhan, N. Jing, R. Lal, C. Krepler, G.V. Long
Journal: Annals of Oncology (2024)
1072TiP Phase I/II dose escalation/expansion trial to evaluate safety and preliminary efficacy of DuoBody-EpCAM×4-1BB (BNT314/GEN1059) alone or in combination with an immune checkpoint inhibitor in patients with malignant solid tumors
Authors: I. Melero, N.J. Lakhani, J. Powderly, A.A. Adjei, J.S. Lopez, L.G. Paz-Ares, I. Moreno Candilejo, F. Thistlethwaite, K.S. Rohrberg, G. Jerusalem, A. Malmberg, A. Ioan-Facsinay, P.J. Upadhyay, B. Tan, R. Bartz, T.B.B. Gaziel, U. Forssmann, I. Celik, C. Gann, L. De Mattos-Arruda
Journal: Annals of Oncology (2024)
577P Results of the phase Ib study of NC410 combined with pembrolizumab in MSS/MSI-L colorectal cancer patients
Authors: E.S. Christenson, S. Kazmi, D. Mahadevan, D. Sohal, S. Manda, A. Martz, S. Kordahi, M. Zika, P. Kothari, S. Kahan, E.A. Barbu, A. Morawski, D. Flies, S.A.R. Langermann, M. Chisamore, S. Fu, R. Wadlow, U. Guha, H. Myint, D. Le
Journal: Annals of Oncology (2024)
1084P Phase II study of AI-designed personalized neoantigen cancer vaccine, EVX-01, in combination with pembrolizumab in advanced melanoma
Authors: M.A.A. Khattak, P.A. Ascierto, P. Queirolo, M. Chisamore, D. Kleine-Kohlbrecher, M. Lausen, N. Viborg, M.A. Pavlidis, R.O. Andersen, T.S. Jepsen, S.F. Thorsen, T. Trolle, B. Rønø, G.V. Long
Journal: Annals of Oncology (2024)
1215P United Kingdom (UK) real world study of adjuvant osimertinib in resected EGFR mutated lung cancer
Authors: R.S. Elghadi, I. Datta, A. Jha, P. Sabeshan, A. Arora, E.C. Bean, E. Dimitrakakis, I.P. Harrison, H.A.M. Hassan, P. Jain, R. Kussaibati, Y. Mangan, D. Muller, D. Osborn, N. Steele, A. Sultan, I. Tsagkaraki, T. Verissimo, G. Walls, T. Newsom-Davis
Journal: Annals of Oncology (2024)
1193P Ethical lung cancer screening selection? Comparison of the European 4 - In The Long Run (4ITLR) criteria with the 2021 USPSTF (US), and HUNT lung cancer risk model in a large Norwegian prospective population-based study
Authors: O.D. Roe, O.T.D. Nguyen, I. Fotopoulos, I. Tsamardinos, V. Lagani
Journal: Annals of Oncology (2024)
1092P Nivolumab plus relatlimab vs nivolumab in previously untreated metastatic or unresectable melanoma: 3-year subgroup analyses from RELATIVITY-047
Authors: D. Schadendorf, H.A. Tawbi, F.S. Hodi, E.J. Lipson, P.A. Ascierto, F.A. Medina Soto, M. Maio, M. Hernberg, J. Mackiewicz, S. Prey, M.K. Mujika Eizmendi, V.G. Atkinson, J.C. Hassel, G. Cinat, S. Keidel, S. Rodriguez, P.T. Wang, S. Dolfi, G.V. Long
Journal: Annals of Oncology (2024)
1056P Real-world usage and adverse events (AE) of immune checkpoint inhibitors (ICI): A large-scale, automated, GDPR-compliant analysis of hospital records
Authors: A.T.L. Verbiest, P.R. Debruyne, I. Bassez, D.L. Delombaerde, L. Tack, C.L. Oeste, L. Deckx, L. Croes, D.F.E. Hens, V. Geldhof, H. Prenen, C. Vulsteke
Journal: Annals of Oncology (2024)
540P Early treatment discontinuation (ETD) in dMMR/MSI-H metastastic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICIs)
Authors: J. Taieb, M. Ambrosini, E.L. Alouani, S. Lonardi, F.A. Sinicrope, M. Decraecker, A. Hollebecque, E. Hafliger, T. Mazard, S. Pernot, P. Parent, M.E. Elez Fernandez, M.J. Overman, P. Jayachandran, V. Nasca, L. Salvatore, R. Guimbaud, C. Cremolini, D. Tougeron, F. Pietrantonio
Journal: Annals of Oncology (2024)
1119P Genomic and transcriptomic predictors of resistance to anti-PD1 monotherapy in patients with advanced melanoma
Authors: W. Wang, J.C. Janssen, K. de Joode, M. Aarts, M. Jalving, J.W. de Groot, H.M. Westgeest, K. Suijkerbuijk, J.B.A.G. Haanen, M. Labots, H.M.W. Verheul, P. Katsikis, A.A.M. Van der Veldt, H. van de Werken
Journal: Annals of Oncology (2024)
1011P Model-informed dose optimization of HFB200301, a TNFR2 agonist monoclonal antibody (mAb), in monotherapy and in combination with the anti-PD-1 mAb tislelizumab (TIS), in patients (pts) with advanced solid tumors
Authors: D. Roda Perez, J. Zugazagoitia, E. Garralda, A.I. Spira, A.B. El-Khoueiry, Y. Zhao, P. Oppelt, X. Lin, S. Xie, M. Chen, J. Gan, G. Wong, J. Russella Pollard, W. Hedrich, J. Pallante, F. Adrian, L. Schweizer, X. Shi, R.H.I. Andtbacka
Journal: Annals of Oncology (2024)
1176P Potential utility of ctDNA to detect false positive PET/CT in the evaluation of lymphoma response
Authors: A. Martín-Muñoz, A. Jiménez-Ubieto, Y. Ruiz-Heredia, L. Rufián, M. Rodríguez, T. Baumann, A. Rodríguez, M. Poza, D. Gil, P. Sarandeses, E. Revilla, G. Figaredo, R. Errazquin, I. Rapado, R. Ayala, J. Martinez-Lopez, S. Barrio Garcia
Journal: Annals of Oncology (2024)
1151P Biochemical and radiological efficacy of systmic lanreotide therapy of patients with advanced, unresectable, non-metastatic paraganglioma/pheochromocytoma (PPGL) sporadic and hereditary
Authors: A.D. Kolasińska-Ćwikła, M. Peczkowska, I. Michałowska, J. Pałucki, K. Roszkowska-Purska, A. Cichocki, R. Samsel, J.B. Cwikla
Journal: Annals of Oncology (2024)
1182P Determination of tumor PSMA expression in prostate cancer from blood using a novel epigenomic liquid biopsy platform
Authors: P. Ravi, A. D'Ippolito, J. Wurster, H. Savignano, H.A. Stoltenberg, R. Trowbridge, N. Borges, T. Tamakloe, S. Kieft, V. Tran, J. Guess, C. Obrien, M. Coyne, A. Gorthi, C. Painter, M. Freedman, M. Eaton, J.C. Barrett, H. Jacene, J.E. Berchuck
Journal: Annals of Oncology (2024)
1006P Phase I dose escalation study of HFB200603, a best-in-class BTLA antagonist monoclonal antibody (mAb), in monotherapy and in combination with the anti-PD-1 mAb tislelizumab (TIS) in adult patients (pts) with advanced solid tumors
Authors: M. De Miguel, A. Landa Magdalena, V. Moreno Garcia, V. Gambardella, J. Menis, G. Daniele, A.B. El-Khoueiry, A.I. Spira, A. Gravina, A.J. Olszanski, O. Rapaic, J. Li, H. Poullain, G. Margall, G. Wong, W. Hedrich, J. Russella Pollard, J. Gan, X. Shi, R.H.I. Andtbacka
Journal: Annals of Oncology (2024)
489P Interfering with the tumor microenvironment of glioblastoma: An in vitro study
Authors: S. Mastantuono, D. Cesselli, P. Del Mestre, I.G. Rolle, I. Manini, A.P. Beltrami, M. Skrap, M. Vindigni, C. Di Loreto
Journal: Annals of Oncology (2024)
562P Acquired genomic alterations on first-line chemotherapy (CT) + cetuximab in advanced colorectal cancer (mCRC): Circulating tumor (ct)DNA analysis of the randomized phase II trial TIME-PRODIGE-28
Authors: V. Boige, O. Bouche, C. Mulot, L. Evesque, M. Ben Abdelghani, J.M. Phelip, L. Mineur, M.P. Galais, A-L. Villing, V. Hautefeuille, C. de la Fouchardiere, D. Genet, S. Lassoued, A. Carnot, E. Mitry, S. Jacquot, D. Serazin, E. Brument, A. Winter, H. Blons
Journal: Annals of Oncology (2024)
1004P Phase I/II trial of ASP1570, a novel diacylglycerol kinase ζ inhibitor, in patients with advanced solid tumors
Authors: D. Olson, A. Dowlati, J.J. Luke, M. Mckean, T. Yoshida, D. Park, S. Kitano, M. Barve, Y. Kaneko, G. Koelsch, S. Soukharev, S. Takeshita, N. Alsharif, N. Hashemi, M.R. Patel
Journal: Annals of Oncology (2024)
1184P Early real-world experience with positive multi-cancer early detection (MCED) test cases and negative initial diagnostic work-up
Authors: C. Westgate, O. Gordon, M. Margolis, Y. Oh, D. Broyles, J. Friedman, W. Jones, J. Ferrell, O. Venn, R. Jiang, S. Leake, E. Hubbell, E.T. Fung, E.A. Klein, J. Venstrom, R.S. Shaknovich, E. O'Donnell
Journal: Annals of Oncology (2024)
1122P The role of imaging during follow-up after radical surgery of stage IIb-c and III cutaneous malignant melanoma: Survival results from an interim analysis of a randomized prospective multicenter study (TRIM)
Authors: C.O. Ladjevardi, Y. Naeser, H. Helgadottir, U. Dyrke, D. Papanoniou, B. Ahringberg-Kald, R. Olofsson Bagge, N. Elander, C. Ingvar, M. Jansson, P. Flygare, C. Nilsson, F. Jakobsson, K. Lange Norström, Y. Brandberg, A. Sundin, G.J. Ullenhag
Journal: Annals of Oncology (2024)
1047P Tocilizumab is an effective secondary prophylaxis during immune checkpoint inhibitor rechallenge following arthritis
Authors: M. Obeid, P-F. Petit, S. Latifyan, D. Daoudlarian, V. Joo, R. Bartolini, H. Bouchaab, N. Mederos Alfonso, K. Abdelhamid, J. Doms, N. Ferahta, L. Mencarelli, A. Stravodimou, K. Shabafrouz, G. Pantaleo, S. Peters
Journal: Annals of Oncology (2024)
1030P Survival rates in high-risk neuroblastoma patients undergoing anti-GD2 immunotherapy: A single arm meta-analysis and systemic review
Authors: L. Escalante Romero, I. Queiroz Costa Neto, V.L.J. Antunes, M. Matos Correia Rodrigues, J.R. Polo Mercado, E. Monteiro Caran
Journal: Annals of Oncology (2024)
1160P An Italian multicenter phase II trial of metronomic temozolomide in unfit patients with advanced neuroendocrine neoplasms: Interim analysis of the MeTe study
Authors: F. Spada, C. Jemos, M. Barberis, E. Pisa, V. Bagnardi, S. Frassoni, S. Boselli, C. Mazzon, D. Tamayo, D. Malengo, E. Omodeo Salè, M. Rossi, F. Gelsomino, S. Pusceddu, L. Benini, C.A. Cella, D. Ciardiello, M.G. Zampino, L. Gervaso, N. Fazio
Journal: Annals of Oncology (2024)
1145MO CVM-005: Phase IIa study of CVM-1118, a novel oral anti-vasculogenic mimicry (VM) agent, in advanced neuroendocrine tumors (NET) after progression on prior therapy
Authors: C.J. Yen, M-H. Chen, Y.Y. Chen, L-Y. Bai, J-S. Chen, J.C-H. Hsieh, Y-H. Shih, I-C. Wu, Y-L. Chen, C-M. Chen, T-Y. Chao, Y-W. Chu, D-S. Chien
Journal: Annals of Oncology (2024)
1012P Safety, tolerability, and efficacy of nadunolimab in combination with pembrolizumab in patients with solid tumors
Authors: R. Cohen, S. Jauhari, A. Jimeno, J. Hreno, L. Sun, M. Wallen Öhman, A. Sanfridson, N. Losic, D. Tersago
Journal: Annals of Oncology (2024)
1172O Akkermansia muciniphila-based multi-omic profiling in advanced non-small cell lung cancer
Authors: L. Belluomini, A. Bonato, A. Almonte, F. Gattazzo, I. Lebhar, R. Birebent, C. Flament, M. Xiberras, M. Marques, P. Ly, C. Thelemaque, C. Parisi, J. Remon Masip, B. Besse, D. Planchard, C. Alves Costa Silva, F. Barlesi, L. Zitvogel, L. Derosa
Journal: Annals of Oncology (2024)
1063P Influence of infusion timing on the outcomes of immunotherapy in a multi-tumor cohort
Authors: V. Albarrán Fernández, D.I. Rosero Rodriguez, J. Chamorro-Perez, P. Guerrero, C. Gonzalez Merino, C. García de Quevedo Suero, P. Sotoca-Rubio, A.M. Barrill Corpa, V. Alia Navarro, J. Moreno, J.C. Calvo, P. Pérez de Aguado, M.V. San Roman Gil, P. Alvarez Ballesteros, C. Saavedra Serrano, A. Soria Rivas, M.E. Olmedo Garcia, P. Garrido Lopez, A. Cortes Salgado, P. Gajate
Journal: Annals of Oncology (2024)
1143O Refining molecular classification of neuroendocrine tumors from diverse origins using multi-omic integration models: Unveiling novel neuroendocrine subtypes and their clinical implications
Authors: C. Carretero-Puche, B. Antón Pascual, A. Lens-Pardo, M. Benavent Viñuales, L. Gomez-Izquierdo, P. Jimenez Fonseca, A. Teijo, Y. Rodríguez, B. Rubio-Cuesta, A. Lamas-Paz, G. Gomez-Lopez, B. Soldevilla, R. Garcia-Carbonero
Journal: Annals of Oncology (2024)
1142O Multivariable analysis of streptozotocin plus 5-fluorouracil and everolimus sequences in advanced pancreatic neuroendocrine tumor patients: The SEQTOR trial (GETNE-1206)
Authors: J. Capdevila Castillon, S. Tafuto, M. Krogh, A. Teule, R. Garcia-Carbonero, H.J. Klumpen, B. Cremer, I. Sevilla, B.K. Eriksson, E. Mitkina Tabaksblat, J-P. Metges, N.S. Reed, J. Schrader, S. Bozzarelli, U. Knigge, P. Jimenez-Fonseca, M. Benavent Viñuales, M. Venerito, V. Navarro, R. Salazar Soler
Journal: Annals of Oncology (2024)
1013P A phase I study of rivoceranib combined with nivolumab in patients with unresectable or metastatic cancer
Authors: N.S. Chawla, C.H. Park, E.M. Gordon, S.P. Chawla, X. Meng, W.R. Strickland, L.A. Finis, C. Galloway
Journal: Annals of Oncology (2024)
1147MO Ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors (RamuNET): An AIO phase II multicenter single-arm study
Authors: S. Krug, L. Apostolidis, A.O. Koenig, A. Rinke, J. Schrader, T.J. Ettrich, H. Jann, M. Oberbeck, D. Hörsch, T.M. Gress, T. Kegel, M. Richter, S. Behl, J. Steighardt, P. Michl
Journal: Annals of Oncology (2024)
1149MO Carcinoid heart disease in patients with advanced small-intestinal neuroendocrine tumours and carcinoid syndrome: A retrospective experience of two centers of excellence
Authors: L. Algeri, L. Falkman, F. Spada, V. Bagnardi, S. Frassoni, S. Boselli, D. Cardinale, M. Zanobini, J. Crona, L. Benini, D. Tamayo, A. Russo, G. Badalamenti, S. Welin, N. Fazio
Journal: Annals of Oncology (2024)
1102P Immune checkpoint inhibitor rechallenge after treatment with tumor-infiltrating lymphocytes in unresectable melanoma
Authors: A. Betof Warner, J.W. Smithy, C. Los, H. Kalvin, N. Hasson, R.N. Amaria, J.A. Andrade Czapla, M. Schollenberger, A. furness, J.C. Hassel, M. Wermke, J.A. Ocejo Gallegos, J. Lutzky, E.J. Lipson, R.J. Sullivan, H. Kluger, K. Panageas, S. Klobuch, J.B.A.G. Haanen, A.N. Shoushtari
Journal: Annals of Oncology (2024)
997MO A first-in-human phase I/Ib study of ATG-037 monotherapy and combination therapy with pembrolizumab in patients with advanced solid tumors: STAMINA-01
Authors: G. Kichenadasse, J. Lombard, M.A.A. Khattak, J. Lundy, A. Tazbirkova, Q. Zhou, Y. Li, A. Kudva, H. Cui, E. Hoe, K.P. Lynch, M. Chisamore, Y-L. Wu
Journal: Annals of Oncology (2024)
1040P Chemotherapy remodels the tumor immune microenvironment to increase the pCR rate of anti-PD-1 neoadjuvant therapy in MSS/pMMR locally advanced colon cancer: A prospective clinical trial and translational study
Authors: C. Cai, Y. Han, P. Gan, Y. Tang, Y. Liu, L. Tang, Y. Peng, X. Zhang, S. Zeng
Journal: Annals of Oncology (2024)
1106P NivoLag-when: International real-world study of combination immunotherapy sequences in melanoma
Authors: M. Guardamagna, C. Gaudy Marqueste, N. Malissen, S. Roy, I. Pires da Silva, G.V. Long, J.W. Smithy, M.A. Postow, F. Dimitriou, R. Dummer, C. Marchi, A. Chaurand, M. Paone, P.A. Ascierto, G. Warrier, E.J. Lipson, M. Erdmann, C. Berking, B. Archambaud, C. Robert
Journal: Annals of Oncology (2024)
983P Updated safety and efficacy of ABSK-011 in advanced hepatocellular carcinoma (aHCC) with FGF19 overexpression from a phase I study
Authors: X-P. Chen, C.J. Yen, P. Huang, C-C. Lin, J. Wang, D. Li, Y. Li, S. Gu, G. Li, X. Du, M. Sun, C. Dai, J. Qian, C. Liu, J. Liu, Z. Zhuang, F. Zhang, G. Kong, Q. Cheng, A-L. Cheng
Journal: Annals of Oncology (2024)
1157P Retreatment with peptide receptor radionuclide therapy (PRRT) in patients (p) with neuroendocrine tumors (NET): Spanish clinical experience from SEPTRALU national registry
Authors: J. Hernando Cubero, N. Martinez Lago, M. Mitjavila, A. Garcia-Burillo, V. Pubul, P. Bello, J.M. Cano, B. Llana, M. Castellón, E. Rodeño, A. Piñeiro, C. Soldevilla, M. Nevares, J. Aller, U. Anido Herranz, B. Carnero Lopez, Z. Nogareda, A. Garcia Alvarez, P. Jimenez Fonseca, J. Capdevila Castillon
Journal: Annals of Oncology (2024)
1077MO Adjuvant nivolumab v placebo in stage IIB/C melanoma: 3-year results from CheckMate 76K
Authors: G.V. Long, M. Del Vecchio, C. Hoeller, J.S. Weber, J.J. Grob, P. Mohr, S. Grabbe, C. Dutriaux, V. Chiarion Sileni, J. Mackiewicz, P. Rutkowski, P. Arenberger, G. Quereux, T. Meniawy, P.A. Ascierto, J. Taube, A. Nassar, W. Wang, J.M. Kirkwood
Journal: Annals of Oncology (2024)
1048P Cardiovascular toxicities in cancer patients treated with immune checkpoint inhibitors: Evidence from a Belgian real-world multicenter study
Authors: D.L. Delombaerde, C.L. Oeste, A.T.L. Verbiest, L. Tack, L. Croes, I. Bassez, D.F.E. Hens, C. Franssen, P.R. Debruyne, H. Prenen, J. De Sutter, C. Vulsteke
Journal: Annals of Oncology (2024)
503O Neoadjuvant nivolumab (nivo) plus relatlimab (rela) in MMR-deficient colon cancer: Results of the NICHE-3 study
Authors: P.G.M. de Gooyer, Y.L. Verschoor, L.D.W. van den Dungen, S. Balduzzi, A.V. Lent, C. Grootscholten, S. Dokter, A.G. den Hartog, J.W.A. Burger, W.H.M. Verbeek, T.S. Aukema, E.R. Hendriks, S.J. Oosterling, R.G.H. Beets-Tan, T.N. Schumacher, J.B.A.G. Haanen, K.F.D. Kuhlmann, M.E. van Leerdam, J.G. van den Berg, M. Chalabi
Journal: Annals of Oncology (2024)
1020P Highly potent and specific bivalent T cell engager (TCE) targeting PRAME on HLA-A*02:01
Authors: L. Dasargyri, S. Jungmichel, N. Alijaj, A. Sobieraj, F. Scheifele, P. Knobel, P. Richle, H. Merten, R. Doerig, A-M. Evangelopoulou, M. Priola, B. Pavlovic, A. Vilarrasa, L-A. Bickel, T. Schleier, G. Acuña, T. Fugmann, S. Biswas, C. Leisner, L. Borras
Journal: Annals of Oncology (2024)
992O Pembrolizumab for HPV-associated recurrent respiratory papillomatosis
Authors: S. Pai, A. Muniappan, J.C. Park, A. Friedman, N. Campbell, S. Krantz, K-Y. Shin, P. Song, T. Carroll, W. Faquin, A. Oneill, R. Franco
Journal: Annals of Oncology (2024)
1100P Anti-PD1 + low-dose anti-CTLA4 immunotherapy pathological response rate in patients with stage III resectable melanoma: Phase III NEOMIMAJOR trial interim analysis
Authors: I.V. Samoylenko, L. Demidov, S. Dziamidava, A. Zimina, V. Kozlov, S. Odintsova, I. Shumskaya, N. Fadeeva, I. Utyashev, K.D. Penkov, D. Stroyakovskiy, D. Kirtbaya, A. Mochalova, A. Sobolev, D. Tansurev, I. Sorokina, Y. Linkova, A.V. Zinkina-Orikhan, A. Siliutina, F. Kriukov
Journal: Annals of Oncology (2024)
950P Outcomes by baseline tumour burden in EMERALD-1: A phase III, randomised, placebo (PBO)-controlled study of durvalumab (D) ± bevacizumab (B) with transarterial chemoembolisation (TACE) in participants (pts) with embolisation-eligible unresectable hepatocellular carcinoma (uHCC)
Authors: M. Kudo, R. Lencioni, J.P. Erinjeri, S.L. Chan, S. Qin, Z. Ren, Y. Arai, J. Heo, V. Breder, M. Bouattour, F. Dayyani, J-H. Yoon, C-F. Chiu, T. Suttichaimongkol, T. Decaens, R. Griffin, C. Morgan, S.K. Ali, K. Balaji, B. Sangro
Journal: Annals of Oncology (2024)
1001MO Initial safety, pharmacokinetics, and anti-tumor activity data of TCER IMA401, a MAGEA4/8-directed half-life extended TCR bispecific, in phase I dose escalation
Authors: M. Wermke, S. Ochsenreither, M. Chatterjee, S. Gröpper, M-F. Häring, D. Heudobler, D. Jäger, A. Bleckmann, S. Spoerl, S. Knop, J.S. Hecker, S. Bunk, N. Hilf, M. Hutt, A. Mayer-Mokler, S. Missel, O. Veremchuk, C. Britten, C. Reinhardt
Journal: Annals of Oncology (2024)
990O Final results from phase I, first-in-human, dose escalation study of a first-in-class anti-ILT2 antibody, SAR444881, alone and with pembrolizumab or cetuximab, in patients with advanced solid tumors
Authors: R. Perets, S.M. Stemmer, R. Geva, T. Golan, M. Fakih, J.E. Cohen, C. Lieu, Z. Jin, P. Lorusso, I. Friedman, M. Hakim, D. Haves Ziv, S. Hashmueli, I. Mandel, T. Ben Moshe, N. Crawford, G. Abbadessa, R. Perez, M. Wu, M. Borad
Journal: Annals of Oncology (2024)
981P Tyrosine kinase inhibitors vs anti-VEGF antibody, combined with anti-PD-1 inhibitors and TACE in the conversion therapy for hepatocellular carcinoma: A retrospective multicenter real-world study
Authors: Q. Ling, H. Jiang, L. Sheng, Y. Zhang, B. Wang, A. Mu, Y. Zhu, S. Zheng
Journal: Annals of Oncology (2024)
964P Lenvatinib (L) and sorafenib (S) in patients (pts) with advanced or unresectable hepatocellular carcinoma (uHCC): An international, multicenter, phase IV study (STELLAR)
Authors: M. Peck Radosavljevic, A.M. Abdelgafur, A. Granito, A. Gasbarrini, Y. Ma, E. Mena, J.L. Lledó-Navarro, J. Presa, A. Weinmann, M.T. Levy, A. Pellicelli, D.T. Waldschmidt, H.T. Sørensen, L. Goyal, M. Ren, H. Saal, C.E. Okpara, T. Meyer
Journal: Annals of Oncology (2024)
1005P Microbial ecosystem therapeutics 4 (MET4) treatment mediates a humoral response in patients treated with immune checkpoint inhibition (ICI)
Authors: P. Spiliopoulou, M. Wong, G.M. Boukhaled, R. Gadalla, S. Strum, R. Liu, A. Heirali, B.X. Wang, S. Saibil, A.R. Hansen, L.L. Siu, B. Coburn, A. Spreafico
Journal: Annals of Oncology (2024)
1271P Integrating machine learning prediction and causal inference analysis to unravel determinants of progression in EGFR-mutant, advanced NSCLC
Authors: H. Bozcuk, L. Sert, M.A. Kaplan, A.M. Tatli, M. Karaca, B. Kilictas, M. Artac, M.A.N. Sendur, B. Bilgin, S. Balli, A. Demirkazik, S. Kilickap, H. Taban, H.G. Güzel, M. Kocer, B. Koylu, F.S. Biricik, G. Karakaya, H.S. Coskun, M.S. Alemdar
Journal: Annals of Oncology (2024)
1014P Phase Ib trial results of safety, pharmacokinetics and pharmacodynamics of TU2218, TGFβ-RI and VEGF-R2 dual inhibitor in combination with pembrolizumab in patients with advanced solid tumors
Authors: A.W. Tolcher, H-T. Kim, D-Y. Oh, K-P. Kim, A. Chaudhry, M. Chaney
Journal: Annals of Oncology (2024)
993MO A phase I, open-label, multicenter, dose escalation safety and tolerability study of oncolytic virus OVV-01 in advanced solid tumors
Authors: Y. Hua, C. Wang, F. Li, Y. Han, D. Zuo, Y. Lv, Y. Peng, J. Chen, R. Yuan, F. Zhang, Y. Wang, H. Wu, G. Zhou, S. Wang, N. Li, Y. Lu, Q. Lin
Journal: Annals of Oncology (2024)
1144O Osteopontin (OPN) predicts the efficacy of anti-angiogenic therapy with multikinase inhibitors (MKIs) in advanced neuroendocrine tumors (NETs): Underlying molecular mechanisms
Authors: A. Lens-Pardo, C. Carretero-Puche, B. Antón Pascual, J. Capdevila Castillon, M. Benavent Viñuales, P. Jimenez Fonseca, E. Grande, C. Perna, A. Caminoa, B. Rubio-Cuesta, J. Sarmentero, B. Gil-Calderón, P. Llamas, B. Soldevilla, R. Garcia-Carbonero
Journal: Annals of Oncology (2024)
979P Initial results from the phase II randomized trial comparing TACE with irinotecan and mitomycin C to doxorubicin in intermediate stage HCC (IRITACE trial)
Authors: O. Waidmann, T. Gruber-Rouh, C. Koch, T.O. Götze, M. Schultheiss, E. Herrmann, C. Steup, J. Trojan, T.J.J. Vogl, S. Zeuzem, F. Finkelmeier
Journal: Annals of Oncology (2024)
1016P Phase I study of SOF10 plus atezolizumab in patients with advanced/recurrent solid tumours
Authors: T. Doi, Y. Kuboki, S. Koganemaru, T. Koyama, J. Sato, Y. Katsuya, E. Ueda, K. Higashikawa, T. Ishida, M. Nakamura, S. Nakagawa, N. Yamamoto
Journal: Annals of Oncology (2024)
996MO Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced/metastatic solid tumors: Data from phase I dose escalation
Authors: J.J. Luke, X. Gao, A.J. Olszanski, R.E. Sanborn, G.S. Falchook, S. Patel, P.L. Bedard, D. Orr, J.P. Gibbs, C. Li, Y-C. Huang, R. Gregory, R. Ramesh, R. Xu, B. Wu, K. Ding, J. Raizer, P. Lorusso
Journal: Annals of Oncology (2024)
1267P Sequential afatinib (AFA) to osimertinib (OSI) in EGFR-mutant NSCLC: Primary analysis of Gio-Tag Japan, a multicenter prospective observational study
Authors: N. Takase, A. Hata, T. Sumi, H. Yoshioka, Y. Fujisaka, T. Ota, J. Osugi, M. Mitsui, R. Morita, S. Morita, K. Sakai, K. Nishio, N. Katakami
Journal: Annals of Oncology (2024)
994MO The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/Rα payloads, in patients with advanced solid tumors
Authors: Y. Shen, S. Rahimian, A. Qin, Y. Qiu, T. Fang, X. Liang, Y. Li, Q. Tan, R. Zhao, X. Bai, T. Liang
Journal: Annals of Oncology (2024)
958P Utilizing personalized tumor-specific methylation haplotypes of circulating tumor DNA for monitoring minimal residual disease in hepatocellular carcinoma patients after curative resection
Authors: X. Yang, D. Guo, S-Y. Zhang, M-J. Xu, H. Chen, C. Ma, M-Y. Su, Q. He, Y. Zhang, Z. Su, R. Liu, J. Fan, J. Zhou
Journal: Annals of Oncology (2024)
976P Tislelizumab plus donafenib combined with transarterial chemoembolization in patients with resected high-risk hepatocellular carcinoma (TIDE): A prospective, single-arm, phase II trial
Authors: W. Peng, Y. Hao, Y. Wei, F. Xie, C. Li, X. Zhang, J. Shen, W. Lu, J. Zhou, T. Wen
Journal: Annals of Oncology (2024)